Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo

Published:2013-09 Issue:9 Volume:2 Page:e70-e70
ISSN:2157-9024
Container-title:Oncogenesis
language:en
Short-container-title:Oncogenesis

Author:

Hashimoto M,Suizu F,Tokuyama W,Noguchi H,Hirata N,Matsuda-Lennikov M,Edamura T,Masuzawa M,Gotoh N,Tanaka S,Noguchi M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology

Link

http://www.nature.com/articles/oncsis201330.pdf

Reference55 articles.

1. Manning BD, Cantley LC . AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261–1274.

2. Scheid MP, Woodgett JR . Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003; 546: 108–112.

3. Cantley LC . The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–1657.

4. Luo J, Manning BD, Cantley LC . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257–262.

5. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998; 279: 710–714.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of lncRNA DLEU2 as a potential diagnostic biomarker and anti-inflammatory target for ulcerative colitis;Frontiers in Pharmacology;2022-09-14

2. Identifying Key MicroRNA Signatures for Neurodegenerative Diseases With Machine Learning Methods;Frontiers in Genetics;2022-04-21

3. Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review;Archives of Medical Science;2021-01-05

4. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene;Biomedicine & Pharmacotherapy;2020-06

5. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia;Investigational New Drugs;2020-01-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3